James D. McKay

Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study

Mark C. Genovese, James D. McKay, Eduardo Mysler et al. · Arthritis & Rheumatism · 2008 · 858 citations

Medicine, Pharmacology, Pharmacotherapy +16

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus

Daniel J. Wallace, William Stohl, Richard Furie et al. · Arthritis Care & Research · 2009 · 595 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double‐blind, placebo‐controlled study

D Alarcón-Segovia, James A. Tumlin, Richard Furie et al. · Arthritis & Rheumatism · 2003 · 244 citations

Life Sciences, Pharmacology, Pharmacotherapy +14

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

Ellen M. Ginzler, Daniel J. Wallace, Joan T. Merrill et al. · The Journal of Rheumatology · 2013 · 182 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long‐term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

Joan T. Merrill, Ellen M. Ginzler, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2012 · 117 citations

Medicine, Clinical Sciences, Pharmacotherapy +11